Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor

British Journal of Clinical Pharmacology

Volumn 74, Issue 2, 2012, Pages 336-345

  Piscitelli, Steve ^a   Kim, Joseph ^a   Gould, Elizabeth ^a   Lou, Yu ^a   White, Scott ^a   de Serres, Mark ^a   Johnson, Mark ^a   Zhou, Xiao Jian ^b   Pietropaolo, Keith ^b   Mayers, Douglas ^b  

^a GLAXOSMITHKLINE   (United States)

^b Idenix Pharmaceuticals Inc   (United States)

Author keywords

Antiretroviral therapy; Drug drug interaction; HIV 1 infection; NNRTI

Indexed keywords

ATAZANAVIR; ATORVASTATIN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DARUNAVIR; DROSPIRENONE PLUS ETHINYLESTRADIOL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSDEVIRINE; LOPINAVIR; RALTEGRAVIR; RITONAVIR; ROSUVASTATIN; SIMVASTATIN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADENINE; ANDROSTENES; ANTI-HIV AGENTS; CONTRACEPTIVES, ORAL; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LEAST-SQUARES ANALYSIS; LINEAR MODELS; LOPINAVIR; MALE; OLIGOPEPTIDES; PATIENT SAFETY; PHOSPHINIC ACIDS; PHOSPHONIC ACIDS; PYRIDINES; PYRIMIDINES; PYRROLES; PYRROLIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RISK ASSESSMENT; RITONAVIR; SIMVASTATIN; SULFONAMIDES;

EID: 84863759763     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04194.x     Document Type: Article

References (12)

1. Richman DD, Jakubik J, Chapron C, Hubbard L, Gray L, Seifer M, Standring DN. Genotypic resistance and phenotypic cross-resistance profile in vitro for a novel NNRTI: IDX899. 2008. Poster presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA.
2. Zhou X-J, Pietropaolo K, Damphousse D, Belanger B, Chen J, Sullivan-Bólyai J, Mayers D. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects. Antimicrob Agents Chemother 2009; 53: 1739-46.
3. White S, Lou Y, Dumont E, Zala C, Zhou X-J, Kim J. Safety, efficacy, pharmacokinetic (PK), and PK/pharmacodynamics (PK/PD) of GSK2248761, a next generation NNRTI, administered as short-term monotherapy in therapy-naïve HIV-1 infected (NV) subjects. 2010. Poster presented at: 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2010; Boston, MA.
4. St Clair M, Dudas K, Lou Y, Zala C, Mayers D, Dumont E. GSK2248761, an NNRTI with activity against common NNRTI resistance mutants, did not select for NNRTI resistance mutations in two seven-day monotherapy studies. 2010. Slides presented at: 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2010; Boston, MA.
5. Ford SL, Kim J, Yu L, Gould E, White S, Piscitelli S, Johnson MA. Inhibition potential for GSK2248761, a next-generation NNRTI, on HMG-CoA reductase inhibitors simvastatin, atorvastatin and rosuvastatin. 2011. Poster presented at: 12th International Workshop on Clinical Pharmacology of HIV Therapy; April 13-15, 2011; Miami, FL.
6. Richman D, Dousson C, Storer R, Moussa A, Randall J, Bridges E, Liuzzi M, Jakubik J, Seifer M, Standring D. IDX12899 and IDX12989, novel NNRTI with potent anti-HIV activity, enhanced barrier to resistance and favorable pharmacokinetic profile. 2007. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA.
7. von Hentig N. Atazanavir/ritonavir: a review of its use in HIV therapy. Drugs Today (Barc) 2008; 44: 103-32.
8. Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005; 44: 1035-50.
9. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33: 1729-39.
10. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, Brobst SW, Segal Y, Aberg JA, the AIDS Clinical Trials Group A5108 Team. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 2005; 39: 307-12.
11. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F, the NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS 2002; 16: 569-77.
12. Schmidt GA, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med 2007; 20: 411-6.